German Federal Joint Committee (G-BA)

On April 19, 2022, the Innovation Committee at the Federal Joint Committee (G-BA) has informed of the favorable results of the scientific evaluation of the G-BA Innovation Fund performed by the economic research center Prognos AG.

On April 4, 2022, the Innovation Committee at the Federal Joint Committee (G-BA) published the decisions, which recommended the transfer to standard care for two completed projects. The projects relate to the management of rare diseases and the strengthening of the regional healthcare structures and processes.

On April 4, 2022, the Innovation Committee at the Federal Joint Committee (G-BA) announced funding from the G-BA Innovation Fund for 18 innovative healthcare research projects dedicated to medical guidelines.

On March 3, 2022, the Innovation Committee at the Federal Joint Committee (G-BA) published the determined funding priorities for new forms of care. A total of seven prioritized topics are defined. The preparation of a complete application can be supported for a period of up to six months with a grant of up to a maximum of €75,000. The deadline for submitting ideas is May 17, 2022, at noon.

On February 17, 2022, the Federal Joint Committee (G-BA) has decided to include the method of matrix-associated autologous chondrocyte implantation (M-ACI) on the knee joint in the case of symptomatic cartilage damage in the lists of reimbursed procedures in the hospital and ambulatory settings.

On February 16, 2022, the Innovation Committee at the Federal Joint Committee (G-BA) has published the decisions which recommended the transfer to standard care for three completed projects. The projects relate to the prevention of antibiotic resistance, improvement of healthcare in socially disadvantaged areas, and misuse of control colonoscopies in Germany.

On January 20, 2022, the Federal Joint Committee (G-BA) has initiated an evaluation procedure for early benefit assessment for the use of a stent retriever (pRELAX by femtos) to treat vasospasm of cerebral arteries after subarachnoid hemorrhage.

On December 16, 2021, the Federal Joint Committee (G-BA) announced the start of the procedure concerning a co-funded study in accordance with §137e of the Social Code Book V (SGB V) for a low-intensity pulsed ultrasound for the treatment of pseudarthroses.

On December 15, 2021, the Innovation Committee at the Federal Joint Committee (G-BA) has announced that seventeen applications for Innovation Funding of the new forms of care were accepted.

On November 12, 2021, the Innovation Committee at the Federal Joint Committee (G-BA) has announced the selection of thirty project ideas for Innovation Funding of the new forms of care within the framework of the two-stage application process. A total of 123 project ideas were received, and only thirty were accepted.

In early-mid November 2021, the Federal Joint Committee (G-BA) has initiated an evaluation procedure for early benefit assessment for two new cardiovascular technologies (Revivent TC™ by BioVentrix and Trilogy™ Heart Valve System by JenaValve Technology) in heart failure, and aortic valve insufficiency and stenosis, respectively.

In late August 2021, the Innovation Committee at the Federal Joint Committee (G-BA) has announced funding of 52 innovative projects on health care research from the G-BA Innovation Fund.